Generix Group - 2017/2018 Financial Result: EBITDA of 8.1%

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
868
Generix Group - 2017/2018 Financial Result: EBITDA of 8.1% of revenue

FINANCIAL PRESS RELEASE

Paris, France, June 6, 2018

2017/2018 Financial Result: EBITDA of 8.1% of revenue

Generix Group, Industrial, Logistical and Retail Ecosystems provider with leading Collaborative Software Solutions, issued today the results for its fiscal year 2017/2018 ended March 31, 2018.

Revenue growth at 12% - EBITDA: 8.1% (+ 3.6 points vs. N-1)

 

The Generix Group has been able to generate 12% growth in the 2017/2018 financial year, including 5% external growth, making it possible to reach revenue of 70.3 million euros through the development and evolution of its SaaS offering abroad, including the launch of the collaborative platform "Generix Supply Chain Hub".

  12 months ended March, 31 Variation
 IFRS consolidated accounts, in millions of Euros 2018 2017 M€ %
Revenues 70,3 63,0 7,3 12%
Which licenses 4,7 4,6 0,0 1%
Which maintenance 18,8 17,6 1,3 7%
Which SaaS 23,8 21,6 2,2 10%
Which Consulting Services 23,0 19,3 3,8 20%
Operational expenses / other income from operations - 67,4 - 61,0 - 6,5 11%
Profit (loss) from current operations 2,9 2,0 0,8 41%
Other operational income and expenses - 0,7 - 0,6 - 0,1 23%
Profit (loss) from operations 2,2 1,5 0,7 47%
Financial expenses - 0,5 -  0,3 -  0,1 38%
Profit (loss) before income taxes 1,7 1,1 0,6 50%
Income taxes benefit - 0,5 - 1,1 0,6 - 55%
Net result after tax 1,2 0,0 1,2 2603%
Net result 0,6 - 0,2 0,7 411%

 

 

  12 months ended March, 31 Variation
EBITDA in millions of euros 2018 2017 M€ %
Revenues 70,3 63,0 7,3 12%
Other income from operations 2,1 1,7 0,4 27%
Cost of goods sold - 0,8 - 1,0 0,2 -19%
Other purchases and external expenses - 21,9 -20,7 - 1,2 6%
Taxes and similar payments - 1,7 - 1,7 - 0,0 1%
Personnel costs - 40,0 -36,1 - 3,9 11%
Other expenses on operations - 1,3 - 0,6 - 0,7 123%
Reversals of used provisions during the period - 0,2 -0,4 0,2 -46%
Capitalized production - 0,7 - 1,4 0,6 -46%
EBITDA (1) 5,7 2,9 2,8 99%

(1)                EBITDA = current operating income + net provisions on current assets + net provisions for risks and charges + depreciation on fixed assets - capitalized production costs.

The group posted EBITDA of 8.1% of revenue (€5.7 million) for the year, an increase of 3.6 points compared to the previous financial year due to:

  • 2 points by Generix Group North America entering the scope of activity on October 3, 2016 (impacting 12 months in 2017/2018 versus 6 months in 2016/2017);  
  • 1.6 points in organic profit growth, the result of growth in a context of stabilization of operating expenses for sales & marketing.

At Group level, the net impact of the activation of software development costs and net depreciation and provisions amounts to -€ 2.8 million compared to -€ 0.8 million as at March 31, 2017. The change in these posts had no impact on cash flow, mainly related to the cost of software development, less depreciation (-€ 1.0 million) and net provisions on current assets (- € 0.5 million). Current operating income nevertheless amounted to €2.9 million, up 41%.

Other operating expenses and income, of -€ 0.7 million, correspond to the initial price supplement paid in connection with the acquisition of Generix North America. As a reminder, the operating expenses of the previous fiscal year corresponded to acquisition-related expenses.

After considering the financial result and the tax effect, net profit amounted to €1.2 million, a clear improvement over the previous year.

Net debt and cash flow

  12 months ended March, 31 Variation
Net debt, in millions of Euros 2018 2017 M€ %
Cash and cash equivalents, end of period 6,2 6,9 - 0,7 - 10%
Short-term and long-term portions of financial obligations - 13,4 - 13,2 - 0,3 2%
Net debt - 7,2 - 6,2 - 1,0 16%
         
  12 months ended March, 31 Variation
Consolidated statements of cash flows, in millions of Euros 2018 2017 M€ %
Net income adjusted by non-cash items 3,9 2,5 1,4 57%
Change in working capital - 1,3 1,7 - 3,0 - 177%
Net cash by operating activities 2,6 4,2 - 1,6 - 38%
Net cash used in investing activities - 2,8 - 8,1 5,3 - 66%
Free cash flow - 0,2 - 3,9 3,7 - 95%
Net cash by financing activities - 0,5 5,3 - 5,8 - 110%
Net increase in cash and cash equivalent - 0,7 1,5 - 2,2 - 148%
Cash and cash equivalent, end of period 6,2 6,9 - 0,7 - 10%

Cash flow for the fiscal year 2017/2018 was primarily characterized by:

  • Improved profitability;
  • Working capital requirements related to growth;
  • Net investment flows of financing close to the previous year and mainly impacted by the acquisition and financing transactions on Generix Group North America.

Prospects

Performance recorded over the past year allows the Group to consider continuing its momentum of revenue and profitability growth for the 2018/2019 financial year. 

Supplemental and non-IFRS Financial Information

Supplemental non-IFRS information (above-mentioned as EBIDTA or net debt) presented in this press release are subject to inherent limitations. It is not based on any comprehensive set of accounting rules or principles and should not be considered as a substitute for IFRS measurements. Also, the Company's supplemental non-IFRS financial information may not be comparable to similarly titled non-IFRS measures used by other companies.

Next financial press release: July 30, 2018, after closing of the stock exchange

Release of first quarter revenues for the fiscal year 2018/2019

About Generix Group

Generix Group is a Collaborative Supply Chain expert present in more than 60 countries, thanks to its subsidiaries and network of partners. 6,000 companies around the world use its SaaS solutions. The group's 550 employees provide daily support for such customers as Carrefour, Danone, FM Logistic, McKesson, Bic, Essilor, Bic and Ferrero in the digital transformation of their Supply Chain.

Its collaborative platform, Generix Supply Chain Hub , helps companies to keep the promises they make to their customers. It combines the capabilities to execute physical flows, digitalize information flows, manage collaborative processes and connect companies to all their partners, in real time.

Generix Supply Chain Hub is aimed at all players in the Supply Chain: manufacturers, third and fourth-party logistics providers (3PL/4PL) and retailers. 

Founded in France in 1990, the company is listed on the Eurolist market of Euronext Paris, compartment C (ISIN: FR0004032795). To learn more: www.generixgroup.com

 

Attachment

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Faith and Resilience in China: The Legacy of the Long March

Updated Category News Views 20

History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...

Continue Reading
Antheia Secures $80M for Critical Medicine Onshoring

Updated Category News Views 22

Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...

Continue Reading
AEVEX Faces 48-Hour Deadline for Investor Class Action

Updated Category News Views 16

Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....

Continue Reading
Lundbeck's Board Leadership Transitions into New Era

Updated Category News Views 10

A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...

Continue Reading
Tomorrowland's Shanghai Return: An Electri-Lifesaver

Updated Category News Views 25

You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...

Continue Reading
ASTS Faces a Legal Countdown – Investors Take Note

Updated Category News Views 11

AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...

Continue Reading
UEG's New Advisory Board: Elevating Patient Voices

Updated Category News Views 21

Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...

Continue Reading

Top 5 Most Recently Viewed Articles

Thermo Fisher's Role as the Leading Partner in Biopharma

Updated Category News Views 212

Thermo Fisher's Role in Revolutionizing Biopharma Thermo Fisher Scientific Inc. (TMO) is increasingly becoming the cornerstone of the biopharma sector. Although some analysts have observed a recent dip in its stock performance, there is a strong belief in its capability to rebound through strategic acquisitions and promising growth prospects. Notably, Thermo Fisher boasts...

Continue Reading
Jamf Unveils Comprehensive Reinvestment Strategy for Growth

Updated Category News Views 161

Jamf's Strategic Reinvestment Initiative In a bold move aimed at enhancing operational efficiency and shareholder value, Jamf (NASDAQ: JAMF) has announced a strategic reinvestment plan designed to propel long-term growth. This initiative comes on the heels of a comprehensive systems update that has illuminated new business opportunities and operational insights. Enhancing...

Continue Reading
Fidelity D & D Bancorp, Inc. Sees Earnings Impact in Q3

Updated Category News Views 46

Fidelity D & D Bancorp, Inc. Announcements on Financial Standing In recent news regarding Fidelity D & D Bancorp, Inc. (NASDAQ: FDBC), the company revealed its latest financial results, marking a significant quarter in their ongoing operations. As of September 30, 2024, Fidelity Bank, under the leadership of President and CEO Daniel J. Santaniello, has recorded key...

Continue Reading
Deutsche Bank Lowers Boeing Price Target, Retains Buy Rating

Updated Category News Views 71

Deutsche Bank's Strategic Assessment of Boeing Recently, Deutsche Bank has made headlines with its updated financial outlook for Boeing (NYSE: BA), decreasing the stock price target from $225.00 to $195.00. However, they have maintained a Buy rating on the aerospace company's shares. This adjustment comes in response to expected larger free cash flow (FCF) burn for the...

Continue Reading
TIGRIS Aquatic Services Expands With LakePro Acquisition

Updated Category News Views 868

TIGRIS Aquatic Services Expands With LakePro Acquisition TIGRIS Aquatic Services, LLC has made a significant move by acquiring LakePro, Inc., a prominent player in the field of aquatic management. This acquisition opens new opportunities for TIGRIS, expanding its operational reach into fresh markets and reinforcing its commitment to creating safe and well-managed water...

Continue Reading